ZAMA: Zanubrutinib Plus Rituximab as Front-line Treatment for Mucosa-associated Lymphoid Tissue Lymphoma (MALT) (clinicaltrials.gov) - Sep 16, 2026 - P2 | N=42 | Active, not recruiting | Sponsor: Sun Yat-sen University | Recruiting ➔ Active, not recruiting | Trial primary completion date: Aug 2028 ➔ Dec 2026
Enrollment closed • Trial primary completion date • Extranodal Marginal Zone Lymphoma • Hematological Malignancies • Lymphoma • Marginal Zone Lymphoma • Oncology
|